It would have been nice if patients who take monthly intravitreal injections of ranibizumab (Lucentis) could have dropped back to quarterly injections instead, but a new study shows a less frequent schedule is also less effective at reducing vision los…
PanOptica completes $30 million Series A financing
PanOptica, Inc., a private biopharmaceutical company focused on licensing and developing innovative ophthalmology therapies, today announced that it has raised $30 million in a Series A financing. This round was led by SV Life Sciences and Third Rock V…
New Research Reveals Unexpected Biological Pathway In Glaucoma
In a study published in the Proceedings of the National Academy of Sciences (Early Edition ahead of print), a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway…
Use Of Amniotic Membrane May Cause Complications In Strabismus Surgery
Postoperative adhesions are a major complication in strabismus surgery. Amniotic membrane has been used in the hopes of preventing these adhesions by forming a biological barrier during healing…
Early Detection Is Vital To Preventing Blindness
It happens slowly. Over time, a person’s vision will get worse. Until one day, that person can no longer see. Glaucoma is the second leading cause of blindness in the United States and worldwide. Unfortunately, there is no cure. Once a person’s vision …
Early Detection Is Vital To Preventing Blindness
It happens slowly. Over time, a person’s vision will get worse. Until one day, that person can no longer see. Glaucoma is the second leading cause of blindness in the United States and worldwide. Unfortunately, there is no cure. Once a person’s vision …